In transplant recipients on chronic immunosuppression, COVID-19 infection is
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.